Clearmind Medicine Inc. (NASDAQ:CMND) Sees Large Drop in Short Interest

Clearmind Medicine Inc. (NASDAQ:CMND) was the recipient of a large drop in short interest during the month of October. As of October 30th, there was short interest totaling 1,160 shares, a drop of 70.0% from the October 15th total of 3,861 shares. Currently, 0.2% of the company’s stock are sold short. Based on an average daily trading volume, of 7,371 shares, the short-interest ratio is currently 0.2 days.

Clearmind Medicine Stock Performance

Shares of Clearmind Medicine stock traded down $0.14 during mid-day trading on Friday, hitting $4.47. 3,427 shares of the stock were exchanged, compared to its average volume of 105,940. Clearmind Medicine has a 12 month low of $4.35 and a 12 month high of $1,272.00. The company has a 50-day simple moving average of $6.51 and a 200 day simple moving average of $40.24. The company has a debt-to-equity ratio of 0.01, a quick ratio of 4.31 and a current ratio of 4.31. The company has a market capitalization of $2.28 million, a P/E ratio of -0.01 and a beta of 0.88.

Clearmind Medicine (NASDAQ:CMND) last announced its earnings results on Thursday, September 10th. The company reported ($4.56) earnings per share for the quarter.

Clearmind Medicine Company Profile

Clearmind Medicine Inc. (NASDAQ: CMND) is a clinical-stage biotechnology company focused on discovering and developing psychedelic-derived therapeutics for underserved health conditions. The company’s research combines medicinal chemistry with the study of psychoactive compounds to identify treatments designed to address substance-use disorders and other metabolic or behavioral conditions. Clearmind’s lead investigational compound is MEAI, also known as 5-methoxy-2-aminoindane. The company has evaluated MEAI in preclinical and early clinical research for potential applications including alcohol use disorder and binge drinking.